

Assembly of the Type III Secretion Apparatus of Enteropathogenic *Escherichia coli*

Tomoaki Ogino,^{1,3,†§} Ryuta Ohno,^{1§} Kachiko Sekiya,² Asaomi Kuwae,^{1,3} Takeshi Matsuzawa,^{1,3} Takashi Nonaka,^{4‡} Hiroyuki Fukuda,⁴ Shinobu Imajoh-Ohmi,⁴ and Akio Abe^{1,3*}

Laboratory of Bacterial Infection, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan¹; Laboratory of Electron Microscopy, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan²; The Kitasato Institute, Tokyo, Japan³; and Laboratory Center for Proteomics Research, Department of Basic Medical Sciences, Institute of Medical Science, University of Tokyo, Tokyo, Japan⁴

Received 18 June 2005/Accepted 3 February 2006

Enteropathogenic *Escherichia coli* (EPEC) secretes many Esps (*E. coli*-secreted proteins) and effectors via the type III secretion (TTS) system. We previously identified a novel needle complex (NC) composed of a basal body and a needle structure containing an expandable EspA sheath-like structure as a central part of the EPEC TTS apparatus. To further investigate the structure and protein components of the EPEC NC, we purified it in successive centrifugal steps. Finally, NCs with long EspA sheath-like structures could be separated from those with short needle structures on the basis of their densities. Although the highly purified NC appeared to lack an inner ring in the basal body, its core structure, composed of an outer ring and a central rod, was observed by transmission electron microscopy. Matrix-assisted laser desorption ionization–time-of-flight mass spectrometry, Western blot, and immunoelectron microscopic analyses revealed that EscC was a major protein component of the outer ring in the core basal body. To investigate the mechanisms of assembly of the basal body, interactions between the presumed components of the EPEC TTS apparatus were analyzed by a glutathione S-transferase pulldown assay. The EscC outer ring protein was associated with both the EscF needle protein and EscD, a presumed inner membrane protein. EscF was also associated with EscJ, a presumed inner ring protein. Furthermore, *escC*, *escD*, and *escJ* mutant strains were unable to produce the TTS apparatus, and thereby the secretion of the Esp proteins and Tir effector was abolished. These results indicate that EscC, EscD, and EscJ are required for the formation of the TTS apparatus.

Enteropathogenic *Escherichia coli* (EPEC) is a major cause of diarrhea in young children (12). This pathogen induces a characteristic histopathological lesion referred to as an attaching/effacing lesion, which is defined by the intimate attachment of bacteria to the epithelial surface and the effacement of host cell microvilli (25). Factors responsible for the formation of attaching/effacing lesions are encoded by a 35-kbp locus designated LEE (24), which encodes the following components: (i) the type III secretion (TTS) apparatus (15), (ii) *E. coli*-secreted proteins (EspA, EspB, and EspD) and several effectors, including Tir, (iii) type III-specific chaperones, and (iv) regulators (9). LEE is highly conserved among enterohemorrhagic *E. coli*, rabbit EPEC, and *Citrobacter rodentium*.

TTS systems are found in many other gram-negative bacterial species, and they constitute a strategy for the delivery of effectors into host cells, a process which in turn disrupts host physiology and thereby contributes to the disease process (14). Unlike the *sec*-dependent secreted proteins, the effector does

not have a typical signal sequence at its N terminus, and it is directly delivered via the TTS system without N-terminal processing in the bacterial periplasm. Analysis by transmission electron microscopy (TEM) revealed that the supermolecular structures of the TTS apparatus in EPEC (8, 31), *Salmonella enterica* serovar Typhimurium (18, 20–22), and *Shigella flexneri* (2, 32) are highly conserved with respect to each other and that their shapes are similar to that of the flagellar basal body complex. The core TTS apparatus, which is referred to as a needle complex (NC), is composed of two distinct portions: (i) a needle structure that extrudes from the bacterial outer membrane and functions as an injector of effectors into host cells and (ii) a cylindrical basal body that is similar to the flagellar basal body and functions as a channel that spans the outer and inner membranes of the bacterium as well as the periplasmic region. The basal body is further divided into three major portions: (i) an outer ring, (ii) an inner ring, and (iii) a presumed central rod (22) that can connect the outer and inner rings to build a channel.

Although the supermolecular structure of the EPEC NC is similar in shape to that of the NCs of both *Salmonella* and *Shigella*, a unique extracellular appendage in the needle structure of the EPEC NC was discovered previously (31). The EPEC needle structure is composed of a thin needle (neck portion) and an expandable sheath-like structure (31). EPEC EscF is predicted to be an 8-kDa protein and may polymerize to form the thin needle in the needle structure. EscF shows homology to PrgI (24% identity) in the *Salmonella* pathogenicity island 1, *Shigella* MxiH (25% identity), and *Yersinia en-*

* Corresponding author. Mailing address: Laboratory of Bacterial Infection, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. Phone: 81 (3) 5791 6123. Fax: 81 (3) 5791 6125. E-mail: abe@lisci.kitasato-u.ac.jp.

† Present address: Department of Molecular Genetics/Section of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195.

‡ Present address: Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8, Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan.

§ These authors contributed equally to this work.

terocolitica YscF (20% identity), which are major components of the thin and stiff needle structures of the *Salmonella*, *Shigella*, and *Yersinia* NCs, respectively (21, 26, 32). EscF is required for NC formation and the secretion of the Esp proteins (31); this observation agrees with findings of secretion-defective phenotypes of *Salmonella prgI* and *Shigella mxiH* mutant strains (21, 32). EspA is predicted to be a 20-kDa protein and is secreted via the EPEC TTS system (17). We previously demonstrated that EspA is directly associated with the tip of the putative EscF needle and polymerizes into an expandable filamentous structure, referred to as the sheath-like structure (31). The EPEC needle structure, including the EspA sheath-like structure, extended to a length of more than 600 nm and was 10 times longer than the *Shigella* needle (45 nm) (31). Three-dimensional structure analysis of the EspA filament revealed that the structure consists of a helical tube with a diameter of 12 nm enclosing a central channel with a diameter of 2.5 nm (7). Recent TEM analysis of purified EspA revealed that EspA alone is able to polymerize into irregular short filaments (33). On the other hand, the widths of the outer and inner membrane rings in the basal body of the EPEC NC are estimated to be 17 and 18 nm, respectively, and the height of the basal body is 31 nm (31). However, the molecular composition of the EPEC NC basal body remains unclear.

From the results of a membrane fractionation study (13), yeast two-hybrid analysis (5), whole mutation analyses of LEE (10), and computer modeling predictions, several proteins are thought to be components for the EPEC TTS apparatus. The outer ring protein of the basal body has been suggested to be EscC, according to a membrane fractionation study (13), and this hypothesis received further support from a demonstration of its similarity to the YscC protein (31.1% identity) in the *Yersinia* TTS system, which forms a ring-shaped oligomeric complex with a diameter of 20 nm in the outer membrane (4, 19). EscC belongs to a member of the secretin superfamily, which participates in the delivery of large molecules through the outer membrane by the formation of a channel. EscC is predicted to be synthesized as a 56-kDa preprotein possessing a signal sequence that is cleavable with type I signal peptidase after amino acid residue 19. Then, the EscC preprotein most likely undergoes signal peptide cleavage after its export across the inner membrane by a *sec*-dependent secretion pathway, thus generating a mature 54-kDa protein. Indeed, a mature form of *Salmonella* InvG, an EscC orthologue, starts at amino acid residue 25, suggesting that its preprotein is cleaved by type I signal peptidase in order to reach maturation (20). Recently, the association of EscC with EscD was suggested by use of a yeast two-hybrid system (5). EscD is predicted to be a 45-kDa protein and shows amino acid sequence similarity to *Yersinia* YscD, a bacterial inner membrane protein (27).

In *Salmonella*, PrgK and PrgH together form the inner membrane ring of the TTS apparatus (18). Although a PrgH orthologue has not been found in EPEC, a PrgK orthologue, EscJ, is thought to form a portion of the inner ring. Molecular modeling using the 1.8-Å crystal structure of EscJ suggests that EscJ oligomerizes to form a large 24-subunit ring structure (34). Furthermore, a membrane fraction study indicates that EscJ localizes mainly to the inner membrane (34). These findings suggest that the inner ring of the EPEC TTS apparatus contains the EscJ multimeric complex. EscJ is predicted to be

TABLE 1. Strains used in this study

Organism and strain	Genotype/description	Reference or source
EPEC		
E2348/69	Prototype EPEC O126:H6 strain	16
ILS002	E2368/69 Δ <i>espA</i>	23
ILS003	E2348/69 Δ <i>escC</i>	This study
ILS004	E2348/69 Δ <i>escD</i>	This study
ILS005	E2348/69 Δ <i>escJ</i>	This study
<i>E. coli</i>		
BL21(DE3)	F ⁻ <i>ompT hsdS_B gal dcm</i> (DE3)	Invitrogen
Sm10 λ <i>pir</i>	Permissive strain for replication of pCVD442	11
DH5 α	<i>hsdR17 deoR thi-1 phoA supE44</i> λ ⁻	Invitrogen

produced as a 21-kDa preprotein with a lipoprotein signal sequence that can be cleaved after amino acid residue 19 by type II signal peptidase. After *sec*-dependent translocation, the EscJ preprotein may undergo lipid modification and signal peptide cleavage to form a mature 19-kDa lipoprotein, which may be anchored to the inner membrane via its N-terminal lipid moiety (34). Although several Esc proteins, namely, EscR, EscS, EscT, and EscU, are predicted to be components of the basal body, their precise functions and localizations in the EPEC TTS apparatus remain unclear.

In this study, we analyzed the structures of NCs isolated from EPEC by using centrifugation techniques, including CsCl density gradient centrifugation. Furthermore, protein components of NCs were examined by matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI-TOF MS), Western blotting, and immunoelectron microscopy. In addition, the protein-protein interactions required for assembly of the EPEC TTS apparatus were analyzed using a glutathione *S*-transferase (GST) pulldown assay, and confirmation of the putative components of the TTS apparatus needed for NC assembly, as well as those needed for the secretion of Esp proteins and the Tir effector, was carried out by the construction of deletion mutants.

MATERIALS AND METHODS

Bacterial strains and growth media. EPEC was grown in Dulbecco's modified Eagle's medium (DMEM) at 37°C, as previously described (31). *Shigella* was grown in Luria-Bertani (LB) broth at 37°C. For details regarding the strains and their genotypes, see Table 1.

Plasmids and oligonucleotides. The plasmids and oligonucleotides used in this study are listed in Tables 2 and 3, respectively.

Cloning and construction of nonpolar mutants. To construct the EPEC *escC* mutant, the 2.0-kbp DNA fragment encoding EscC and its flanking regions was amplified by PCR with the primers B1-*escC* and B2-*escC*, using EPEC E2348/69 genomic DNA as the template. Likewise, to construct EscD and EscJ mutants, the 1.2- and 1.2-kbp DNA fragments encoding EscD and EscJ and their respective flanking regions were amplified by PCR with the following sets of primer pairs: B1-*escD* and B2-*escD* and B1-*escJ* and B2-*escJ*. The resulting PCR products were cloned into pDONR201 to obtain pDONR-*escC*, pDONR-*escD*, and pDONR-*escJ* by means of adapter PCR and site-specific recombination techniques using the Gateway cloning system (Invitrogen). By using circular pDONR-*escC*, -*escD*, and -*escJ* as the DNA templates, inverse PCR was carried out with the following sets of primer pairs, respectively: R1-*escC* and R2-*escC*, R1-*escD* and R2-*escD*, and R1-*escJ* and R2-*escJ*. The resulting PCR products were digested with the respective restriction enzymes, which were generated in R1 and R2 primers and self-ligated to obtain pDONR- Δ *escC*, pDONR- Δ *escD*, and pDONR- Δ *escJ*, respectively. pDONR- Δ *escC* contained the stop codon and the BglIII restriction site in addition to a 180-bp deletion starting 3 bp down-

TABLE 2. Plasmids used in this study

Plasmid	Description	Reference or source
pABB-CRS2	Positive-selection suicide vector	31
pDONR201	Gateway cloning vector	Invitrogen
pDONR- <i>escC</i>	<i>escC</i> cloned into pDONR201	This study
pDONR- <i>escD</i>	<i>escD</i> cloned into pDONR201	This study
pDONR- <i>escJ</i>	<i>escJ</i> cloned into pDONR201	This study
pDONR-GST- <i>escD</i>	<i>escD</i> cloned into pDONR201	This study
pDONR-GST- <i>escF</i>	<i>escF</i> cloned into pDONR201	This study
pDONR- <i>escD</i> -V5	<i>escD</i> cloned into pDONR201	This study
pDONR- <i>escF</i> -V5	<i>escF</i> cloned into pDONR201	This study
pABB- <i>ΔescC</i>	<i>escC</i> deletion in pABB-CRS2	This study
pABB- <i>ΔescD</i>	<i>escD</i> deletion in pABB-CRS2	This study
pABB- <i>ΔescJ</i>	<i>escJ</i> deletion in pABB-CRS2	This study
pTrc99A	Prokaryotic expression vector	Pharmacia
pABB-Trc99cm	pTrc99A-derived vector	31
p99- <i>escC</i>	<i>escC</i> cloned into pABB-Trc99cm	This study
p99- <i>escD</i>	<i>escD</i> cloned into pABB-Trc99cm	This study
p99- <i>escJ</i>	<i>escJ</i> cloned into pABB-Trc99cm	This study
p99- <i>espA</i>	<i>espA</i> cloned into pABB-Trc99cm	31
pGEX-6P-1	GST fusion protein expression vector	Amersham
pGEX- <i>escC</i>	<i>escC</i> cloned into pGEX-6P-1	This study
pGEX- <i>escJ</i>	<i>escJ</i> cloned into pGEX-6P-1	This study
pDEST15	GST fusion protein expression vector	Invitrogen
p15- <i>escD</i>	<i>escD</i> cloned into pDEST15	This study
p15- <i>escF</i>	<i>escF</i> cloned into pDEST15	This study
pBAD-DEST49	V5-tagged protein expression vector	Invitrogen
p99 <i>ccdB</i> -V5	V5-tagged protein expression vector derived from pTrc99A	This study
p99- <i>escD</i> -V5	<i>escD</i> cloned into p99 <i>ccdB</i> -V5	This study
p99- <i>escF</i> -V5	<i>escF</i> cloned into p99 <i>ccdB</i> -V5	This study

stream from the *escC* start codon. pDONR-*ΔescD* contained the stop codon and the XhoI restriction site in addition to a 70-bp deletion starting 565 bp downstream from the *escD* start codon. pDONR-*ΔescJ* contained the stop codon and the BglII restriction site in addition to a 148-bp deletion starting 196 bp downstream from the *escJ* start codon. pDONR-*ΔescC*, pDONR-*ΔescD*, and pDONR-*ΔescJ* were then mixed with a positive suicide vector, pABB-CRS2 (31), to obtain pABB-*ΔescC*, pABB-*ΔescD*, and pABB-*ΔescJ*, respectively, by the Gateway cloning system. These plasmids were introduced separately into *E. coli* SM10λpir and transconjugated into the EPEC wild-type (WT) strain (nalidixic acid resistant), as described previously (11). The resulting mutant strains were designated strains *ΔescC*, *ΔescD*, and *ΔescJ*, respectively.

For complementation of the *espA* defect in EPEC, p99-*espA* was constructed by cloning the DNA fragment containing *espA* into pABB-Trc99cm (31), which can replicate in EPEC. A DNA fragment of *espA* was amplified by PCR with the primer pair B1-*espA*com and B2-*espA*com, using EPEC genomic DNA as the template. Likewise, DNA fragments for *escC*, *escD*, and *escJ* were amplified by PCR with the following sets of primer pairs, respectively: B1-*escC*com and B2-*escC*com, B1-*escD*com and B2-*escD*com, and B1-*escJ*com and B2-*escJ*com. The resulting PCR products of *espA*, *escC*, *escD*, and *escJ* were mixed with pDONR201, and then each recombinant plasmid was mixed with pABB-Trc99cm (31) to obtain p99-*espA*, p99-*escC*, p99-*escD*, and p99-*escJ*, respectively, by the Gateway cloning system. These p99 series were used for complementation of strains *ΔespA*, *ΔescC*, *ΔescD*, and *ΔescJ*.

For the pulldown assay, each DNA fragment encoding EscC, EscD, EscF, and EscJ was amplified by PCR using EPEC E2348/69 genomic DNA as the template with the following sets of primer pairs, respectively: 5GST-*escC* and 3GST-*escC*, 5GST-*escD* and 3GST-*escD*, 5GST-*escF* and 3GST-*escF*, and 5GST-*escJ* and 3GST-*escJ*.

3GST-*escJ*. PCR products of *escC* or *escD* were digested with BamHI and EcoRI and were then inserted into the BamHI and EcoRI sites of pGEX-6P-1 to obtain pGEX-*escC* or pGEX-*escJ*, respectively. PCR products of *escD* or *escF* were mixed with pDONR201 to obtain pDONR-GST-*escD* or pDONR-GST-*escF*, respectively, and then each recombinant was mixed with pDEST15 to obtain p15-*espD* or p15-*escF*, respectively, by using site-specific recombination techniques and the Gateway cloning system. For the addition of the V5 epitope tag at the C terminus, a plasmid, p99*ccdB*-V5, was constructed from pTrc99A and pBAD-DEST49. The 1.8-kbp DNA fragment encoding the chloramphenicol resistance gene, the *ccdB* gene for negative selection, the gene encoding the V5 epitope tag, and specific recombination sites (*attR1* and *attR2*) was amplified by PCR with R1V5HIS and R2V53 primers, using pBAD-DEST49 (Invitrogen) as the DNA template. The resulting PCR product was digested with SacI and XbaI and then inserted into the SacI and XbaI sites of pTrc99A to obtain p99*ccdB*-V5. To construct EscD-V5 and EscF-V5, DNA fragments encoding either EspD or EscF were amplified from EPEC E2348/69 genomic DNA by adapter PCR with the following sets of primer pairs, respectively: B1-*escD*-V5 and B2-*escD*-V5 and B1-*escF*-V5 and B2-*escF*-V5. The resulting PCR products were cloned into pDONR201 to obtain pDONR-*escD*-V5 and pDONR-*escF*-V5, respectively, using the Gateway cloning system. pDONR-*escD*-V5 and pDONR-*escF*-V5 were then mixed with p99*ccdB*-V5 to obtain p99-*escD*-V5 or p99-*escF*-V5, respectively, using the Gateway cloning system.

Purification of the NCs from EPEC. Whole-cell lysates were prepared from EPEC WT and mutant strains according to the protocol used for *Shigella* (32). The whole-cell lysates were clarified by centrifugation at $16,000 \times g_{av}$ (where g_{av} is average gravity) for 20 min at 4°C and were then subjected to ultracentrifugation in a Hitachi RP42 rotor at $80,000 \times g_{av}$ for 1 h at 4°C. The resulting pellets containing the NCs were resuspended in TET buffer (10 mM Tris-HCl [pH 8.0 at 20°C], 1 mM EDTA, and 0.1% Triton X-100). Following centrifugation at $17,000 \times g_{av}$ for 10 min, the resulting supernatant was recovered and is designated NC fraction I (NC fr. I). To further purify the EPEC NCs, NC fr. I (3 ml, 0.3 mg of protein/ml) from a 3-liter culture of the *espA* mutant harboring cloned *espA* in *trans* (*ΔespA/A* strain) (31) was layered on 1.5 ml of a sucrose cushion (30% [wt/vol] sucrose, 10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA) and then centrifuged in a Beckman SW55 rotor at $170,000 \times g_{av}$ for 4 h at 4°C. The resulting pellet was resuspended in TET buffer, and then the suspension was centrifuged at $17,000 \times g_{av}$ for 10 min. The resulting supernatant (1.2 ml, 0.05 mg of protein/ml) was recovered and is referred to as NC fraction II (NC fr. II). To isolate the NCs, NC fr. II was subjected to CsCl density gradient centrifugation. NC fr. II (1 ml) was mixed with 4 ml of TET buffer containing 1.9 g of CsCl to give an initial density of 1.28 g/cm³; the sample was then centrifuged to equilibrium in the SW55 rotor at $90,000 \times g_{av}$ for 24 h at 20°C. Twenty fractions (250 μl each) were collected from the top of the gradient, diluted to a volume of 3 ml with TET buffer, and then centrifuged in a Beckman TLA-100.4 rotor at $80,000 \times g_{av}$ for 1 h at 4°C. The respective pellets were resuspended in 0.25 ml of TET buffer. The protein concentrations were determined according to the method of Bradford (3) by using bovine serum albumin as a standard.

Electron microscopy. Samples were negatively stained with 2% phosphotungstic acid (pH 7.3) in a solution containing 0.2% (wt/vol) sucrose on Butval-98 grids. The samples were then observed under a JEM 1010 transmission electron microscope (JEOL, Tokyo, Japan). For the immunolabeling of the NCs, samples were applied to Butval-98 grids, fixed with 1% formaldehyde in physiological salt solution, and immunolabeled first with affinity-purified anti-EspA or anti-EscC polyclonal antibodies and subsequently with 6-nm colloidal gold-conjugated antibodies against guinea pig immunoglobulin G (Aurion, Wageningen, The Netherlands) at room temperature for 20 min.

MALDI-TOF MS analysis. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out, the protein bands were stained with Coomassie brilliant blue (CBB) and excised from the polyacrylamide gel. Proteins in the excised gel fragments were digested with modified trypsin (sequencing grade; Roche Molecular Biochemicals), and the resulting peptides were analyzed using a Voyager-DE PRO MALDI mass spectrometer (Applied Biosystems). Peptide mass fingerprint searches were performed with the Mascot search program, which is available at the Matrix Science website (www.matrixscience.com).

Preparations of secreted proteins. EPEC grown in DMEM was removed by centrifugation at $17,000 \times g_{av}$ for 10 min, and the proteins in the supernatants were precipitated by trichloroacetic acid at a concentration of 10% and then analyzed by SDS-PAGE.

GST pulldown assay. *E. coli* DH5α carrying p99-*escD*-V5 or p99-*escF*-V5 was incubated overnight at 30°C with shaking; the overnight cultures were then diluted 1:40 in LB broth containing 50 μg/ml ampicillin and incubated for 4 h at 30°C with shaking. The bacterial culture was further incubated for 4 h at 30°C in the presence of IPTG (isopropyl-β-D-thiogalactopyranoside) at a final concen-

TABLE 3. Oligonucleotides used in this study

Oligonucleotide	Sequence ^a	Cleavage site
B1- <i>escC</i> B2- <i>escC</i>	5'-AAAAAGCAGGCTGCTGCTATTTGTTTGACAGTGGCA-3' 5'-AGAAAGCTGGGTAACGTTACGTTTTTATCAAGAATCG-3'	
R1- <i>escC</i> R2- <i>escC</i>	5'-GAAGATCTTTACATTACACAATTCGTCCTA-3' 5'-GAAGATCTTGAATGATGATTTCTCTGGCGA-3'	BglII BglII
B1- <i>escD</i> B2- <i>escD</i>	5'-AAAAAGCAGGCTTCATGTTATCCTCATATAAAATTA-3' 5'-AGAAAGCTGGGTTAATACGACAGTGGAAATATGTA-3'	
R1- <i>escD</i> R2- <i>escD</i>	5'-CCGCTCGAGTGGAGTTAATCCGTGGTTG-3' 5'-CCGCTCGAGCCGCAATTAATGATGTCTTAACG-3'	XhoI XhoI
B1- <i>escJ</i> B2- <i>escJ</i>	5'-AAAAAGCAGGCTCATATCCCGTTAGCATCA-3' 5'-AGAAAGCTGGGTTGGCAAAGATACCACTTC-3'	
R1- <i>escJ</i> R2- <i>escJ</i>	5'-GAAGATCTTATTGCGGAACTTAATCCTC-3' 5'-GAAGATCTAATACCCGGTGTATCGATTG-3'	BglII BglII
B1- <i>espAcom</i> B2- <i>espAcom</i>	5'-AAAAAGCAGGCTATTATAAGGAGGATGTTATGTG-3' 5'-AGAAAGCTGGGTCACAGACTGGATATCGTT-3'	
B1- <i>escCcom</i> B2- <i>escCcom</i>	5'-AAAAAGCAGGCTGATGCCGCCAACACACT-3' 5'-AGAAAGCTGGGTGGTCATTGAGATCTTGTGTGTC-3'	
B1- <i>escDcom</i> B2- <i>escDcom</i>	5'-AAAAAGCAGGCTCATTAGCCATTGAAACTCAC-3' 5'-AGAAAGCTGGGTGTATCCTGGTAATCAAGTCTCT-3'	
B1- <i>escJcom</i> B2- <i>escJcom</i>	5'-AAAAAGCAGGCTCATATCCCGTTAGCATCA-3' 5'-AGAAAGCTGGGTTGGCAAAGARACCACTTC-3'	
5GST- <i>escC</i> 3GST- <i>escC</i>	5'-CGGGATCCGCCCGTCTCTCTGGAA-3' 5'-CGGAATTCCTTATTCGCTAGATGCAGATTTTAT-3'	BamHI EcoRI
5GST- <i>escJ</i> 3GST- <i>escJ</i>	5'-CGGGATCCTGATAAGAGCAATTGTATACAG-3' 5'-CGGAATTCCTTACCCGTCTGTCTGAGGAT-3'	BamHI EcoRI
5GST- <i>escD</i> 3GST- <i>escD</i>	5'-AAAAAGCAGGCTTCATGTTATCCTCATATAAAATA-3' 5'-AGAAAGCTGGGTTAATACGACAGTGGAAATATGTA-3'	
5GST- <i>escF</i> 3GST- <i>escF</i>	5'-AAAAAGCAGGCTTCTGGAAGTTCTGTTCCAGGGGCCCATGAATTTATC TGAAATTAC-3' 5'-AGAAAGCTGGGTTAAAAACTACGGTTAGAAATG-3'	PreScission protease
R1V5HIS R2V53	5'-GCGAGCTCACAAAGTTTGTACAAAAAAGCTGAA-3' 5'-GCTCTAGATTAACCGGTACGCGTAGAATCGAG-3'	SacI XbaI
B1- <i>escD-V5</i> B2- <i>escD-V5</i>	5'-AAAAAGCAGGCTCCATATTTTTTCTCATTGTTCAACC-3' 5'-AGAAAGCTGGGTTATACGACAGTGGAAATATGTATAGA-3'	
B1- <i>escF-V5</i> B2- <i>escF-V5</i>	5'-AAAAAGCAGGCTGTTTCGTAATGAACGTAAATAGTTAA-3' 5'-AGAAAGCTGGGTTAAAAACTACGGTTAGAAATGGTTGA-3'	

^a Underlining indicates restriction enzyme sites or, for 5GST-*escF*, a region encoding a recognition site for PreScission protease.

tration of 1 mM. Bacteria were collected by centrifugation at $17,000 \times g_{av}$ for 10 min and suspended in cold bead binding buffer (50 mM potassium phosphate [pH 7.2], 150 mM KCl, 1 mM MgCl₂). Bacterial suspensions were sonicated, and the cell debris was removed by centrifugation at $17,000 \times g_{av}$ for 10 min. Triton X-100 and glycerol were added to the supernatants to final concentrations of 1% and 10%, respectively, and their protein concentrations were adjusted to 3.5 mg/ml with cold bead binding buffer. The resulting *E. coli* whole-cell extracts were used for the GST pull-down assay.

GST fusion proteins of EscC, EscD, EscF, and EscJ were expressed in *E. coli* BL21(DE3) containing the respective GST expression vectors pGEX-*escC*, pGEX-*escJ*, p15-*escD*, and p15-*escF*, as listed in Table 2. The whole-cell extracts of the respective bacteria were prepared as described above, and the respective GST fusion proteins were purified from the extracts with glutathione Sepharose 4 Fast Flow (Amersham Biosciences) according to the manufacturer's instruc-

tions. The respective GST-EscC, -EscD, -EscF, and -EscJ fusion proteins (20 μg), bound to glutathione beads (20 μl of 50% slurry), were incubated with the whole-cell extract (400 μl) of *E. coli* DH5α expressing EscC-V5 or EscF-V5 for 4 h at 4°C with gentle shaking. After the beads had been washed three times in cold bead binding buffer, 40 μl of 2× Laemmli sample buffer (200 mM Tris-HCl [pH 6.8], 4 mM EDTA, 4% SDS, 40% glycerol, 10 mM dithiothreitol, 0.02% bromophenol blue) was added to the beads. After the samples were boiled for 5 min, the proteins eluted from the beads were analyzed by 14% SDS-PAGE, followed by immunoblot analysis, as described below.

Antibodies and immunoblotting. A mouse monoclonal antibody against Tir was kindly provided by B. Brett Finlay (Michael Smith Laboratories, University of British Columbia). The guinea pig polyclonal antibodies against EspA and EscC used here were characterized previously (31). EscC or EscF tagged with V5 epitope was detected by anti-V5 monoclonal antibodies (Invitrogen). For the




FIG. 1. Purification of the EPEC NCs. (A) Purification scheme for the EPEC NCs. Whole-cell lysate was prepared from an EPEC $\Delta espA/A$ strain grown in DMEM, and the lysate was clarified by centrifugation. The resulting supernatant fraction (sup fr.) was ultracentrifuged, and then a pellet fraction (ppt fr.) (NC fr. I) was recovered. NC fr. I was layered on a sucrose cushion and then ultracentrifuged. The resulting pellet fraction (NC fr. II) was subjected to CsCl density gradient centrifugation, and then 20 fractions (CsCl frs. 1 to 20) were collected from the top of the gradient. For more details, see Materials and Methods. (B) Electron micrographs of negatively stained EPEC NCs. NC frs. I and II and CsCl fractions 3, 7, 11, and 14 were negatively stained and observed by TEM. White arrows indicate the basal bodies of the EPEC NCs, and black arrows indicate ring structures that were presumed to be the BfpB-BfpG complexes (29). Bar, 250 nm.

immunoblot analysis, proteins were resolved by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon filter; Millipore). The proteins were detected by immunoblotting using an ECL detection kit (Amersham Biosciences).

RESULTS

Purification of the NCs from EPEC. In our previous study, we partially purified the NCs from EPEC, and the supermolecular structure of these NCs was analyzed by TEM (31). In order to further investigate the molecular composition and fine structure of these NCs, we attempted to isolate them from an *espA* mutant harboring cloned *espA* in *trans* ($\Delta espA/A$ strain). This strain produces larger amounts of the NC with longer sheath-like structures than does the WT strain (31). However, the supermolecular structure of the basal body is identical in both strains (31). As illustrated in Fig. 1A, the whole-cell lysate of the $\Delta espA/A$ strain was clarified by centrifugation at $16,000 \times g$ and then the supernatant fraction was centrifuged at $80,000 \times g$ for 1 h to sediment the NCs. The resulting pellet fraction, NC fr. I, was layered on a 30% sucrose cushion and centrifuged at $170,000 \times g$ for 4 h. The high-molecular-weight complexes, including the NCs, were precipitated through the sucrose cushion and were then resuspended in TET buffer in order to recover the pellet fraction, NC fr. II. Finally, NC fr. II was subjected to CsCl density gradient centrifugation at an initial density of 1.28 g/cm^3 . After centrifugation, 20 fractions (CsCl frs. 1 to 20) were obtained from the top to the bottom of the

gradient. At the respective purification steps, representative fractions were negatively stained, and the resulting samples were observed by TEM (Fig. 1B). As expected (31), a large number of other bacterial components was still observed in NC fr. I, but the number of other components was substantially lower in the case of NC fr. II. After CsCl density gradient centrifugation of NC fr. II, the NCs with various needle lengths were separated into various density fractions from 2 to 15 (e.g., CsCl frs. 3, 7, 11, and 14 [Fig. 1B]). Interestingly, the NCs with shorter needle structures accumulated in the low-density fractions 2 to 4 (e.g., CsCl fr. 3). In contrast, NCs with longer sheath-like structures at the tip of the thin needles accumulated in the high-density fractions 13 to 15 (e.g., CsCl fr. 14). In these high-density fractions, the NCs were purified to apparent homogeneity. Furthermore, the length of the sheath-like structure tended to increase gradually with increases in density of the CsCl fractions (e.g., CsCl frs. 7, 11, and 14). Thus, we established a method of distinguishing between the EPEC NCs showing heterogeneity in terms of the length of the needle structure; here, separation was achieved on the basis of the respective densities of these NCs in CsCl solution.

Identification of the protein composition of the EPEC NCs. To investigate the protein components of the NCs, CsCl fractions 1 to 20 were analyzed by SDS-PAGE followed by silver staining (Fig. 2A). The NCs appeared to be copurified with a polypeptide with an apparent molecular mass of 56 kDa (p56) (CsCl frs. 2 to 15). Furthermore, a polypeptide with an appar-




FIG. 2. Identification of EscC and EspA as components of the EPEC NC. (A) NC fr. I (4.5 μ g), NC fr. II (0.3 μ g), and CsCl fractions 1 to 20 (6 μ l each), shown in Fig. 1, were analyzed by 12% SDS-PAGE followed by silver staining. The positions of marker proteins are shown on the left. The positions of p56/EscC, p24/EspA, p84/AceF, and p55/BfpB are shown on the right. (B) Western blot analysis of NC fr. I, NC fr. II, and the CsCl fractions. Samples corresponding to those shown in panel A were immunoblotted with anti-EscC (upper panel) or -EspA (lower panel) antibodies. (C) Distribution of EspA and EscC in the CsCl fractions. Relative amounts of EspA and EscC in the CsCl fractions were estimated from the band densities observed on the Western blots (panel B) by using the NIH Image program. Densities (g/cm^3) of the fractions were determined by refractometry.

ent molecular mass of 24 kDa (p24) was abundant in the high-density fractions 13 to 15, which contained an abundance of NCs with the longer sheath-like structures. To identify p56 and p24, their tryptic fragments were analyzed by MALDI-TOF MS. The peptide mass fingerprints of p56 and p24 were well-matched with the theoretically derived values for EscC (a putative outer ring protein of the EPEC NC basal body) and EspA (a component of the sheath-like structure), respectively (data not shown). Moreover, Western blot analysis revealed that anti-EscC and -EspA antibodies reacted specifically with p56 and p24, respectively, in various fractions (Fig. 2B). From these results, p56 and p24 were identified as EscC and EspA, respectively. In this context, it is of note that EscC (p56) and EspA (p24) migrated more slowly than was expected from

their calculated molecular masses (54 and 20 kDa, respectively) (Fig. 2A). To further analyze the distributions of EspA and EscC in the CsCl fractions, the band intensities of the Western blots (Fig. 2B) were measured by using the NIH Image program, and their relative amounts were estimated (Fig. 2C). Interestingly, EscC was distributed throughout various density fractions (frs. 2 to 15), with two apparent peaks at fractions 3 and 14 (Fig. 2B and C). In contrast, EspA was detected primarily in the high-density fractions 13 to 15 (Fig. 2B and C). The distributions of EspA and EscC in the CsCl density gradient were reproducible for three independently purified preparations. These results strongly indicate that the EPEC NCs with various needle lengths have heterogeneous densities; furthermore, these densities might be determined by the number of EspA molecules per basal body possessing a constant number of EscC molecules. Fractions 2 to 8 also contained a polypeptide with an apparent molecular mass of 55 kDa (p55), which migrated close to p56/EscC on the SDS-polyacrylamide gel; this band thereby appeared as a doublet band (Fig. 2A). According to the results of the MALDI-TOF MS analysis, p55 was thought to be an outer membrane lipoprotein, BfpB, which belongs to the secretin superfamily and is a component of a basal body of the type IV bundle-forming pilus (Bfp) (data not shown). BfpB is known to be associated with BfpG to form an outer ring with a diameter of approximately 20 nm (29). Indeed, ring-shaped supermolecular structures, the size and shape of which were quite similar to the previously reported BfpB-BfpG ring, were detected in fractions 2 to 8 (Fig. 1B, CsCl frs. 3 and 7) but not in fractions 9 to 15 (Fig. 1B, CsCl frs. 11 and 14). Thus, EPEC NCs with the longer sheath-like structures among these fractions were completely separated from the components of Bfp by CsCl density gradient centrifugation. In addition, a polypeptide with an apparent molecular mass of 84 kDa (p84), which was present in fractions 4 to 12, was thought to be a dihydrolipoamide acetyltransferase component (AceF) of the pyruvate dehydrogenase complex, based on the MALDI-TOF MS findings (data not shown). However, we were unable to detect any other proteins that were copurified with EscC or EspA, which suggests that the other NC components were not abundant and/or were easily dissociated from the NCs during the bacterial membrane solubilization and purification of the NCs. In addition, it is possible that some integral membrane and/or multimeric proteins comprising the EPEC NC might not be well resolved on a traditional SDS-polyacrylamide gel, thereby reducing the number of proteins available for the MALDI-TOF MS analysis.

Supermolecular structures of the EPEC NCs. The representative TEM images were obtained from NC fr. I and four CsCl fractions, and a total of 11 images were aligned; the present supermolecular structures were compared with each other and with those of *Shigella* (Fig. 3A). The TEM images clearly showed that the length of the needle structures containing the EspA sheath-like structures detected in the low-density CsCl fractions (e.g., CsCl frs. 3 and 7) was shorter than that in the high-density fractions (e.g., CsCl frs. 11 and 14) (Fig. 1B and 3A); moreover, these observations agree with the results of the Western blot analysis using anti-EspA antibodies (Fig. 2C). To verify the relationship between the densities of the NCs and their respective needle lengths, we examined the distribution of needle length in randomly chosen NCs from CsCl fractions




FIG. 3. Supermolecular structures of the EPEC NCs. (A) Alignment of the EPEC and *Shigella* NCs detected in NC frs. I and CsCl fractions 3, 7, 11, and 14. Bar, 100 nm. (B) Presumed model of the EPEC NC core structure. The size of each structure is given in nanometers. (C) Distribution of needle length in the NCs, as detected in CsCl fractions 3, 7, 11, and 14. The densities (ρ , g/cm^3) of the CsCl fractions are shown in each panel. The average needle lengths were determined by measuring those of 100 (frs. 3, 7, and 11) or 200 (fr. 14) particles. The values represent means \pm standard deviations.

3, 7, 11, and 14 (Fig. 3C) (100 particles of NCs were measured from frs. 3, 7, and 11, and 200 particles were measured from fr. 14). The NCs with a buoyant density in CsCl of 1.240 g/cm^3 (CsCl fr. 3) had shorter needles, and the needle length appeared to be of an almost fixed size (average, 24 nm). In response to the elongation of the EspA sheath-like structure, the density of the NCs appeared to gradually increase. For example, NCs with densities of 1.255 g/cm^3 (CsCl fr. 7) and 1.280 g/cm^3 (CsCl fr. 11) had needle structures with average lengths of 48 and 101 nm, respectively. The NCs with a density of 1.298 g/cm^3 (CsCl fr. 14) had longer needles of various lengths (av-

erage, 335 nm). These findings indicate that the observed increase in the density of the NCs was dependent on the length of the EspA sheath-like structure. Regarding cases in which the needle structure of the NC was longer than 100 nm, the majority appeared to accumulate in the high-density fractions 13 to 15.

The purpose of purifying the EPEC NC was to identify all of the protein components of the TTS apparatus. However, the inner ring of the EPEC NC appears to be unstable during bacterial membrane solubilization and/or during precipitation of the NC through the sucrose cushion. Thus, NCs with the

inner rings were still observed, but only in small amounts, in NC fr. I. However, we detected only NCs without the inner rings in NC fr. II and the CsCl fractions. In contrast, we detected the typical form of the *Shigella* NC (Fig. 3A), which was recovered according to the same methods of membrane solubilization and preparation of NC fr. I. Unlike the EPEC NC, most of the *Shigella* NCs had a typical inner ring. These observations suggest that the components and stability of the EPEC NC may differ from those of the *Shigella* NC, which has a more rigid inner ring structure. Improvement of the conditions for bacterial membrane solubilization is therefore still necessary for the further analysis of the inner ring portion of the EPEC NC. However, taking into account the instability of the EPEC NC basal body, we were able to dissect a central rod of the basal body of the EPEC NC for the first time; this central rod is typically covered by the inner ring that is predicted to contain a multimeric complex of EscJ (34) (Fig. 3A). We measured each of 10 NCs from three CsCl fractions (frs. 3, 7 and 14; a total of 30 NCs), and each part was estimated as shown in Fig. 3B. The length of the central rod, which contained a small ring-like structure (10 nm in width), was estimated to be 20 nm. The width of the stem portion of the central rod was estimated to be 9 nm, which is identical in size to the neck portion (9 nm in width) of the needle structure.

Localization of EscC into the basal body. In order to elucidate the localization of EscC in the EPEC NC, highly purified NCs (CsCl fr. 14) were stained with immunogold-labeled anti-EscC antibodies and observed by TEM (Fig. 4). As expected from our previous results obtained using partially purified NCs (31), the sheath-like structures of the NCs were stained specifically with the anti-EspA antibodies (Fig. 4A). In contrast, the outer rings of the NCs were clearly stained with anti-EscC antibodies, indicating that EscC oligomerizes to form the outer ring of the NC (Fig. 4B).

Composition and assembly of the EPEC NC. The TEM view showed that the basal body appears to be unstable, specifically in terms of the inner ring of the basal body (Fig. 1B and 3A). For this reason, we were unable to determine all of the components of the EPEC TTS apparatus by MALDI-TOF MS analysis. In our previous study, we demonstrated that EscF is required for NC formation and for the secretion of the Esp proteins (31). However, we could not detect EscF in the CsCl fractions by immunoblotting (data not shown); this result was most likely due to the low abundance of EscF in the NC and/or the low quality of our anti-EscF antibody. To further analyze the protein-protein interactions required to assemble the EPEC TTS apparatus, we performed a GST pulldown assay using purified GST-EscD (a presumed component of the basal body), GST-EscJ (a presumed component of the inner ring), GST-EscC (the outer ring protein), and GST-EscF (the needle protein) as the probes (Fig. 5A). Whole-cell extracts were prepared from *E. coli* expressing EscD or EscF tagged with the V5 epitope at the C terminus (EscD-V5 or EscF-V5), and then the extracts were incubated with the respective GST probes bound on glutathione beads. Afterwards, the V5 epitope-tagged proteins coprecipitated with the respective GST probes were detected by Western blotting using anti-V5 epitope antibodies (Fig. 5B). EscD-V5 was associated with GST-EscD as well as with GST-EscC and GST-EscF but not with GST alone. In this experiment, we could not detect the interaction between EscD




FIG. 4. Localization of EspA and EscC in the EPEC NC. The highly purified NCs in CsCl fraction 14 (Fig. 1) were analyzed by immunoelectron microscopy. (A) EspA was detected with immunogold-labeled anti-EspA antibodies. Sheath-like structures coated with 6-nm gold particles were observed. (B) EscC was detected with immunogold-labeled anti-EscC antibodies. In contrast to EspA localization in the sheath, EscC was localized in the basal body of the EPEC NC. Bar, 100 nm.

and EscJ. In contrast, EscF-V5 was associated with GST-EscF, GST-EscC, GST-EscD, and GST-EscJ but not with GST alone. Although the GST pulldown assay may not be a suitable procedure for multimeric and/or membrane-associated proteins, these results suggest that the presumed components of the EPEC TTS apparatus, EscD, EscJ, and EscF, are associated with other components of the EPEC NC.

Effects of mutations in the presumed basal component genes on secretion. We have demonstrated that a mutant strain unable to synthesize EscF, a putative component of the NC thin needle, failed to produce a functional TTS system, thereby preventing the secretion of type III secreted proteins (31). To investigate the effects of *escC*, *escD*, and *escJ* mutations on type III secretion, the secreted proteins from the respective mutant strains ($\Delta escC$, $\Delta escD$, and $\Delta escJ$) were analyzed by 12% SDS-PAGE. As shown in Fig. 6A, the secretion of EspA, EspB, and




FIG. 5. Interactions between the putative components of the EPEC TTS apparatus. (A) Purified GST-Esc fusion proteins were analyzed by 12% SDS-PAGE followed by CBB staining. Arrowheads indicate presumed bands corresponding to the respective GST fusion proteins. Lane M indicates the size markers. (B) Interactions of Esc proteins in a GST pull-down assay. Whole-cell extracts from *E. coli* expressing EscD or EscF tagged with the V5 epitope (EscD-V5 or EscF-V5) were incubated with each agarose-immobilized GST-Esc protein. Proteins bound to the beads were resolved by 14% SDS-PAGE and then analyzed by Western blotting using anti-V5 monoclonal antibodies.

EspD, but not that of EspC (a non-TTS system-secreted protein), was blocked by each of the respective mutations in *escC*, *escD*, or *escJ*. Complementation of the *escC*, *escD*, and *escJ* mutants with the respective genes *in trans* restored the secretion of all of the type III secreted proteins. Therefore, all mutations were nonpolar and could be complemented. To analyze the effects of the above-described mutations on the expression of type III secreted proteins, the secreted proteins and whole-cell extracts from the mutant and complemented strains were analyzed by Western blotting using anti-Tir and anti-EspA antibodies (Fig. 6B). Although neither the production of EspA nor that of Tir in the bacteria was affected by any of the mutations in *escC*, *escD*, or *escJ*, their secretion into the culture supernatants was blocked, indicating that EscC, EscD, and EscJ are required for the secretion of the type III secreted proteins.

Interestingly, when the *escD* clone was introduced into the *escD* mutant strain *in trans* ($\Delta escD/D$), secretion of the Tir effector was greatly increased compared to Tir secretion from $\Delta escC/C$ and $\Delta escJ/J$. In contrast, the level of EspA secretion in $\Delta escD/D$ was almost same as that in both $\Delta escC/C$ and $\Delta escJ/J$. Our findings suggest that EscD may independently regulate the levels of secretion of the Esp proteins and the Tir effector. However, $\Delta escD/D$ has not yet been well characterized. In




FIG. 6. Effect of *esc* mutations on secretion of the Esp proteins and Tir effector. (A) Secreted-protein profiles of WT EPEC and various mutant strains. Bacteria were grown in DMEM, and the secreted proteins were resolved by 12% SDS-PAGE and stained with CBB. (B) Immunoblot analysis of Tir and EspA in the culture supernatants (Sup.) and whole-cell extracts (Cell). Anti-EspA and -Tir antibodies were used for immunodetection. Lanes M and WT indicate the size markers and secreted proteins prepared from the EPEC wild type, respectively.

particular, it will still be necessary to compare the levels of EscD expression and NC formation in $\Delta escD/D$ with those of the other strains.

DISCUSSION

We established a method for the purification of EPEC NCs in successive centrifugal steps (Fig. 1). At the final step of purification, EPEC NCs were separated into various density fractions by equilibrium CsCl density gradient centrifugation (Fig. 1B). The NCs with the shorter needle structures were fractionated into the low-density fractions 2 to 4 ($\rho = 1.23$ to 1.25 g/cm³). Although the densities of the NCs gradually increased to some extent with elongation of the sheath-like needle structures, the majority of the NCs with needle lengths of more than 100 nm were found to have accumulated in the high-density fractions 13 to 15 ($\rho = 1.29$ to 1.30 g/cm³). EspA was more abundant in the high-density fractions than in the low-density fractions (Fig. 2), which was consistent with the observation that the EspA sheath-like needle structures of the NCs in the high-density fractions were longer than those in the low-density fractions (Fig. 3). These findings indicate that the length of the sheath-like structure is correlated with the amount of EspA attached to the NC. The present results also suggest that NCs with a

very small amount of EspA have an inherent buoyant density ($\rho = 1.23$ to 1.25 g/cm³) in the CsCl gradient and that the densities of NCs gradually increase with increases in the number of EspA molecules in NCs of up to 1.29 to 1.30 g/cm³. The density of NCs with the longer EspA sheath-like structure is likely to be comparable to that of the EspA filaments. In other words, NCs with longer EspA sheath-like structures may behave as the EspA filaments, and, when observed in terms of a CsCl gradient, the density of the EspA filaments may not be affected by their length. The needle length of the EPEC NC was almost fixed (24 nm) in CsCl fraction 3, which contained relatively little EspA (Fig. 2B). Interestingly, the shape of the needle tip of the EPEC NC in the low-density fractions differed somewhat from that of the needle tip of the *Shigella* NC, i.e., certain appendages appeared to be attached to the needle tip (Fig. 3A). One hypothesis that could account for these findings would be that a small amount of EspA binds to the tip of the EscF thin needle.

In this study, we clearly demonstrated by immunoelectron microscopy using anti-EscC antibodies that EscC is a major protein component of the NC outer ring with a diameter of 17 nm (Fig. 3B and 4B). EscC was detected in the outer membrane fraction (13) and was required for the secretion of the Esp proteins and Tir (Fig. 6). EscC shares 31.1% identity with *Yersinia* YscC, which belongs to the family of secretins, and forms a ring-shaped oligomeric complex (diameter, 20 nm) (4, 19). The YscC ring-like oligomer is thought to function as a transport channel for macromolecules in the outer membrane. However, the localizations of both EscC and YscC in their respective NCs have not yet been characterized. Here, we carried out an immunoelectron microscopic analysis to demonstrate that EscC is indeed localized in the NC as the outer ring.

The supermolecular structure of the central rod beneath the EscC outer ring could be observed in this study due to the instability of the structure composed of inner membrane proteins (Fig. 3B). The width (9 nm) of the stem in the central rod was identical to that (9 nm) of the neck portion in the needle, suggesting that EscF, a putative major component of the thin needle structure, or an EscF-like protein may form the central rod passing through the EscC outer ring. Although we were unable to identify the component(s) of the central rod, which contained a small ring structure, in the NCs examined here, the composition of the EPEC NC was predicted based on the results of a GST pulldown assay (Fig. 5). As expected, EscF associates with itself, suggesting that EscF may polymerize and thereby construct the thin hollow needle. We also detected the EscF-EscC interaction, which suggested that the EscF needle is sustained by the EscC outer ring. Interestingly, we detected an interaction of EscF with EscJ, which has been predicted to form a periplasmic portion of the inner ring (34). Our present results indicate that EscJ interacts with EscF; this interaction may be required to connect the EscJ inner ring to the external needle structure. Crystal packing analysis and molecular modeling suggest that EscJ oligomerizes to form a large 24-subunit ring structure with a diameter of 18 nm and a height of 5.2 nm. These estimated values are well matched to our previous report for the inner ring with a diameter of 18.1 ± 2.5 nm from electron microscope images of partially purified EPEC NCs (31). The central channel of the modeled EscJ ring is surrounded by the prominent negatively charged trench about 3.2

nm in height and 1.1 nm in width at the periplasmic side (34), and this trench may function as the binding region for the central rod (34). From the results of the GST pulldown assay, we speculate that the EscF thin needle also functions as the central rod. Although the PrgJ rod connecting the InvG outer ring to the PrgH-PrgK inner ring has been considered based on structural analysis of the *Salmonella* NC (22), no orthologue of PrgJ has been identified in EPEC. Furthermore, a PrgH orthologue, MxiG, was previously identified as a component of the NC basal body in *Shigella*. Again, no orthologue of PrgH has been found in EPEC or in *Yersinia*. These findings indicate that structures of both the central rod and the basal body of EPEC are somewhat different from those of *Salmonella* and *Shigella*.

A recent study of the *Shigella* NC assembly using in vivo binding assays demonstrated that MxiD, an EscC orthologue, interacted with MxiJ, an EscJ orthologue (30). From those findings (30), a segment of MxiD is thought to extend into the periplasm, where it can associate with inner membrane proteins such as MxiJ to build or sustain the basal body. Based on the sequence similarities, EscJ is thought to be associated with EscC to form the basal body. However, Creasey et al. (5) detected the EscC-EscD interaction but not the EscC-EscJ interaction by use of a yeast two-hybrid system. In this study, we showed the EscC-EscD and EscD-EscF interactions by using a GST pulldown assay (Fig. 5). EscD shows amino acid sequence similarity to *Yersinia* YscD, the bacterial inner membrane protein (27), but has no orthologue in the *Shigella* and *Salmonella* TTS systems. In addition, EscD contains a putative transmembrane domain (120 to 141 amino acids) at its N terminus (as predicted by TMPred [http://www.ch.embnet.org/software/TMPRED_form.html]). Although the correct localization of EscD in the EPEC NC remains unclear, the transmembrane domain of EscD may associate with the inner membrane and a segment of EscD may be located in the periplasm in order to sustain the central rod, where it can interact with EscC and also with EscF.

We demonstrated that EscC, EscD, and EscJ are required for the secretion of both the Esp proteins and the Tir effector (Fig. 6). These results were supported by mutation analyses of EPEC and/or *C. rodentium* LEE (6, 10, 13, 34) and could be predicted from the similarity of these proteins to YscC, YscD, and YscJ, which are required for the secretion of Yop proteins in *Yersinia* (1, 27). To demonstrate the direct contribution of EscC, EscD, and EscJ to the NC assembly, NC fractions were prepared from all of the mutant strains and observed by TEM. Although the putative BfpB-BfpG ring was observed in all of the mutant strains, no NCs were detected in the case of the *escC*, *escD*, and *escJ* mutants (data not shown). In contrast, the NCs were restored in complemented strains ($\Delta escC/C$, $\Delta escD/D$, and $\Delta escJ/J$), indicating that EscC, EscD, and EscJ are all required for EPEC NC assembly (data not shown). In addition, wild-type EPEC was found to accumulate actin beneath the adherent bacteria by the translocation of Tir via the TTS system (28). In contrast, the *escC*, *escD*, and *escJ* mutant strains did not induce actin cytoskeletal rearrangement (data not shown).

In this study, we isolated the core TTS apparatus from EPEC and revealed the localization of EscC to the outer ring and the structure of the central rod in the TTS apparatus by

electron microscopy. Furthermore, we showed that EscC, EscD, and EscJ are required for the formation of the functional TTS apparatus. Biochemical and genetic studies to identify all structural proteins of the EPEC TTS system and to evaluate their precise roles in assembly of the TTS apparatus are under way.

ACKNOWLEDGMENTS

This research was partially supported by the Ministry of Education, Science, Sports, and Culture of Japan through Grants-in-Aid for Scientific Research (C, 16590370 [2004]), for Young Scientists (B, 14770123 [2002 to 2003]), for Scientific Research on Priority Areas (14021109 [2002]), and for COE research. Support was also received in the form of operating grants from the All Kitasato Project Study and a Kitasato University Research Grant for Young Researchers (2002 to 2004). T.M. is a research fellow of the Japan Society for the Promotion of Science.

REFERENCES

- Allaoui, A., R. Schulte, and G. R. Cornelis. 1995. Mutational analysis of the *Yersinia enterocolitica* *virC* operon: characterization of *yscE*, *F*, *G*, *I*, *J*, *K* required for Yop secretion and *yscH* encoding YopR. *Mol. Microbiol.* **18**: 343–355.
- Blocker, A., N. Jouihri, E. Larquet, P. Gounon, F. Ebel, C. Parsot, P. Sansonetti, and A. Allaoui. 2001. Structure and composition of the *Shigella flexneri* 'needle complex', a part of its type III secretion. *Mol. Microbiol.* **39**:652–663.
- Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**:248–254.
- Burghout, P., R. van Boxtel, P. Van Gelder, P. Ringler, S. A. Muller, J. Tommassen, and M. Koster. 2004. Structure and electrophysiological properties of the YscC secretin from the type III secretion system of *Yersinia enterocolitica*. *J. Bacteriol.* **186**:4645–4654.
- Creasey, E. A., R. M. Delahay, S. J. Daniell, and G. Frankel. 2003. Yeast two-hybrid system survey of interactions between LEE-encoded proteins of enteropathogenic *Escherichia coli*. *Microbiology* **149**:2093–2106.
- Crepin, V. F., S. Prasanna, R. K. Shaw, R. K. Wilson, E. Creasey, C. M. Abe, S. Knutton, G. Frankel, and S. Matthews. 2005. Structural and functional studies of the enteropathogenic *Escherichia coli* type III needle complex protein EscJ. *Mol. Microbiol.* **55**:1658–1670.
- Daniell, S. J., E. Kocsis, E. Morris, S. Knutton, F. P. Booy, and G. Frankel. 2003. 3D structure of EspA filaments from enteropathogenic *Escherichia coli*. *Mol. Microbiol.* **49**:301–308.
- Daniell, S. J., N. Takahashi, R. Wilson, D. Friedberg, I. Rosenshine, F. P. Booy, R. K. Shaw, S. Knutton, G. Frankel, and S. Aizawa. 2001. The filamentous type III secretion translocon of enteropathogenic *Escherichia coli*. *Cell. Microbiol.* **3**:865–871.
- Dean, P., M. Maresca, and B. Kenny. 2005. EPEC's weapons of mass subversion. *Curr. Opin. Microbiol.* **8**:28–34.
- Deng, W., J. L. Puente, S. Gruenheid, Y. Li, B. A. Vallance, A. Vazquez, J. Barba, J. A. Ibarra, P. O'Donnell, P. Metalnikov, K. Ashman, S. Lee, D. Goode, T. Pawson, and B. B. Finlay. 2004. Dissecting virulence: systematic and functional analyses of a pathogenicity island. *Proc. Natl. Acad. Sci. USA* **101**:3597–3602.
- Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an *ae* deletion mutant of enteropathogenic *Escherichia coli* by using a positive-selection suicide vector. *Infect. Immun.* **59**:4310–4317.
- Donnenberg, M. S., and J. B. Kaper. 1992. Enteropathogenic *Escherichia coli*. *Infect. Immun.* **60**:3953–3961.
- Gauthier, A., J. L. Puente, and B. B. Finlay. 2003. Secretin of the enteropathogenic *Escherichia coli* type III secretion system requires components of the type III apparatus for assembly and localization. *Infect. Immun.* **71**:3310–3319.
- Hueck, C. J. 1998. Type III protein secretion systems in bacterial pathogens of animals and plants. *Microbiol. Mol. Biol. Rev.* **62**:379–433.
- Jarvis, K. G., J. A. Giron, A. E. Jerse, T. K. McDaniel, M. S. Donnenberg, and J. B. Kaper. 1995. Enteropathogenic *Escherichia coli* contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proc. Natl. Acad. Sci. USA* **92**:7996–8000.
- Kenny, B., R. Deviney, M. Stein, D. J. Reinscheid, E. A. Frey, and B. B. Finlay. 1997. Enteropathogenic *E. coli* (EPEC) transfers its receptor for intimate adherence into mammalian cells. *Cell* **91**:511–520.
- Kenny, B., L. C. Lai, B. B. Finlay, and M. S. Donnenberg. 1996. EspA, a protein secreted by enteropathogenic *Escherichia coli*, is required to induce signals in epithelial cells. *Mol. Microbiol.* **20**:313–323.
- Kimbrough, T. G., and S. I. Miller. 2000. Contribution of *Salmonella typhimurium* type III secretion components to needle complex formation. *Proc. Natl. Acad. Sci. USA* **97**:11008–11013.
- Koster, M., W. Bitter, H. de Cock, A. Allaoui, G. R. Cornelis, and J. Tommassen. 1997. The outer membrane component, YscC, of the Yop secretion machinery of *Yersinia enterocolitica* forms a ring-shaped multimeric complex. *Mol. Microbiol.* **26**:789–797.
- Kubori, T., Y. Matsushima, D. Nakamura, J. Uralil, M. Lara-Tejero, A. Sukhan, J. E. Galan, and S. I. Aizawa. 1998. Supramolecular structure of the *Salmonella typhimurium* type III protein secretion system. *Science* **280**:602–605.
- Kubori, T., A. Sukhan, S. I. Aizawa, and J. E. Galan. 2000. Molecular characterization and assembly of the needle complex of the *Salmonella typhimurium* type III protein secretion system. *Proc. Natl. Acad. Sci. USA* **97**:10225–10230.
- Marlovits, T. C., T. Kubori, A. Sukhan, D. R. Thomas, J. E. Galan, and V. M. Unger. 2004. Structural insights into the assembly of the type III secretion needle complex. *Science* **306**:1040–1042.
- Matsuzawa, T., A. Kuwae, S. Yoshida, C. Sasakawa, and A. Abe. 2004. Enteropathogenic *Escherichia coli* activates the RhoA signaling pathway via the stimulation of GEF-H1. *EMBO J.* **23**:3570–3582.
- McDaniel, T. K., K. G. Jarvis, M. S. Donnenberg, and J. B. Kaper. 1995. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. *Proc. Natl. Acad. Sci. USA* **92**:1664–1668.
- Moon, H. W., S. C. Whipp, R. A. Argenzio, M. M. Levine, and R. A. Giannella. 1983. Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. *Infect. Immun.* **41**:1340–1351.
- Mueller, C. A., P. Broz, S. A. Muller, P. Ringler, F. Erne-Brand, I. Sorg, M. Kuhn, A. Engel, and G. R. Cornelis. 2005. The V-antigen of *Yersinia* forms a distinct structure at the tip of injectisome needles. *Science* **310**:674–676.
- Plano, G. V., and S. C. Straley. 1995. Mutations in *yscC*, *yscD*, and *yscG* prevent high-level expression and secretion of V antigen and Yops in *Yersinia pestis*. *J. Bacteriol.* **177**:3843–3854.
- Rosenshine, I., M. S. Donnenberg, J. B. Kaper, and B. B. Finlay. 1992. Signal transduction between enteropathogenic *Escherichia coli* (EPEC) and epithelial cells: EPEC induces tyrosine phosphorylation of host cell proteins to initiate cytoskeletal rearrangement and bacterial uptake. *EMBO J.* **11**:3551–3560.
- Schmidt, S. A., D. Bieber, S. W. Ramer, J. Hwang, C. Y. Wu, and G. Schoolnik. 2001. Structure-function analysis of BfpB, a secretin-like protein encoded by the bundle-forming-pilus operon of enteropathogenic *Escherichia coli*. *J. Bacteriol.* **183**:4848–4859.
- Schuch, R., and A. T. Maurelli. 2001. MxiM and MxiJ, base elements of the Mxi-Spa type III secretion system of *Shigella*, interact with and stabilize the MxiD secretin in the cell envelope. *J. Bacteriol.* **183**:6991–6998.
- Sekiya, K., M. Ohishi, T. Ogino, K. Tamano, C. Sasakawa, and A. Abe. 2001. Supermolecular structure of the enteropathogenic *Escherichia coli* type III secretion system and its direct interaction with the EspA-sheath-like structure. *Proc. Natl. Acad. Sci. USA* **98**:11638–11643.
- Tamano, K., S. Aizawa, E. Katayama, T. Nonaka, S. Imajoh-Ohmi, A. Kuwae, S. Nagai, and C. Sasakawa. 2000. Supramolecular structure of the *Shigella* type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors. *EMBO J.* **19**:3876–3887.
- Yip, C. K., B. B. Finlay, and N. C. Strynadka. 2005. Structural characterization of a type III secretion system filament protein in complex with its chaperone. *Nat. Struct. Mol. Biol.* **12**:75–81.
- Yip, C. K., T. G. Kimbrough, H. B. Felise, M. Vuckovic, N. A. Thomas, R. A. Pfuetzner, E. A. Frey, B. B. Finlay, S. I. Miller, and N. C. Strynadka. 2005. Structural characterization of the molecular platform for type III secretion system assembly. *Nature* **435**:702–707.